Clinical spectrum and therapeutic management of auto-immune myelofibrosis: a nation-wide study of 30 cases
Open Access
- 28 May 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (3), 871-874
- https://doi.org/10.3324/haematol.2020.249896
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesHaematologica, 2016
- Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literatureHuman Pathology, 2014
- Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patternsLeukemia Research, 2013
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportBlood, 2013
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic ExperienceMayo Clinic Proceedings, 2012
- Autoimmunity and the risk of myeloproliferative neoplasmsHaematologica, 2010
- Primary autoimmune myelofibrosis: Definition of a distinct clinicopathologic syndromeAmerican Journal of Hematology, 2002
- Range of antinuclear antibodies in “healthy” individualsArthritis & Rheumatism, 1997
- Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus.1994
- Autoimmune MyelofibrosisMedicine, 1994